Repression of Smad-dependent transforming growth factor-β signaling by Epstein-Barr virus latent membrane protein 1 through nuclear factor-κB
✍ Scribed by Naoki Mori; Mariko Morishita; Tomoo Tsukazaki; Naoki Yamamoto
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- French
- Weight
- 307 KB
- Volume
- 105
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
EBV‐encoded LMP‐1 is absolutely required for EBV transformation of cells. Previous studies showed that LMP‐1 is responsible for mediating resistance to the anti‐proliferative effects of TGF‐β that characterizes EBV‐transformed cells. To clarify the mechanisms of resistance to TGF‐β by LMP‐1, we examined the effect of expression of LMP‐1 on the activity of TGF‐β‐responsive promoters. Interestingly, LMP‐1 inhibited TGF‐β‐responsive promoters activity despite lack of direct interaction of LMP‐1 and Smad proteins, intracellular signaling molecules in the TGF‐β signal transduction pathway. Although TGF‐β treatment increased the expression of p15, TGF‐β‐induced gene, this effect was counteracted by expression of LMP‐1. The repressive effect was mapped to the NF‐κB activation domains in the cytoplasmic carboxyl terminus of LMP‐1. Furthermore, LMP‐1‐mediated inhibition of TGF‐β‐responsive promoter was markedly restored after inhibition of NF‐κB activity. LMP‐1 failed to affect receptor‐dependent formation of heteromers containing Smad proteins as well as the DNA‐binding activity of Smad proteins. Overexpression of the transcriptional coactivator CBP and p300 abrogated the inhibitory effect of LMP‐1 on the TGF‐β‐responsive promoter. Our results suggest that LMP‐1 represses the TGF‐β signaling through the NF‐κB signaling pathway at transcriptional level by competing for a limited pool of transcriptional coactivators. These results enhance our understanding of the molecular mechanisms of viral pathogenesis in EBV‐associated malignancies. © 2003 Wiley‐Liss, Inc.